Summary:
U.S. Patent 4,314,081, filed by Bristol-Myers Squibb in 1979 and issued in 1982, covers a chemical compound related to antineoplastic agents, specifically the class of pyridopyrimidines used in cancer treatment. Its claims cover specific chemical structures and methods of use, providing broad protection within this compound class. The patent landscape reveals that subsequent patents (notably in the 1990s and 2000s) have built on this core, both in chemical modification and therapeutic indications. However, the patent has faced expiration or near-term expiration due to its age, affecting exclusivity and commercial opportunities.
What Is the Scope of U.S. Patent 4,314,081?
Chemical Composition Claims:
The patent claims include a class of pyridopyrimidine compounds characterized by a core structure with specified substitutions at particular positions. These modifications influence pharmacokinetics, potency, and selectivity.
Key Claim Details:
- Claims 1-4 define the chemical core and allowable substituents, covering compounds with certain heteroaryl groups, alkyl groups, and halogens.
- Claims 5-8 specify pharmaceutical compositions containing these compounds and methods of use against neoplasms.
Claim Breadth:
The claims encompass a broad class of pyridopyrimidines with varied substitutions, potentially covering numerous analogs created for optimized activity. However, the core structural elements—certain fused ring systems and specific substituents—are central to the claims.
What Are the Major Features and Limitations of the Claims?
Features:
- Focus on pyridopyrimidines with specific substitutions at key positions.
- Claims cover derivatives with potential antitumor activity.
- Includes claims for pharmaceutical compositions and methods of use, broadening enforceability into therapeutic areas.
Limitations:
- Limited specificity: the claims specify certain substituents but do not cover all possible derivatives.
- Expiration risk: the patent’s filing date indicates expiration around 2000-2002, reducing market exclusivity.
- Existing prior art: various pyridopyrimidine derivatives disclosed elsewhere prior to the patent may limit the scope for new patents around these compounds.
Patent Landscape Analysis
Key Patent Families and Related Patents:
- European and Japanese counterparts filed shortly after the U.S. patent, with some extending protection into other jurisdictions.
- Several subsequent patents (e.g., filed in the late 1980s and 1990s) cite 4,314,081 as prior art, especially in patents claiming specific derivatives or new methods of use.
- Patents have been filed around pharmaceutical compositions, delivery methods, and specific therapeutic indications such as lung cancer, breast cancer, and other malignancies.
Innovator and Follow-On Patents:
- Follow-on patents extend the original chemical class with modifications aimed at improving bioavailability, reducing toxicity, or broadening the scope of diseases treated.
- Some patents (e.g., U.S. Patent Nos. 5,514,545 and 6,007,841) claim derivatives with enhanced anti-cancer activity, citing 4,314,081 as foundational.
Expiration and Commercial Impact:
- The original patent has likely expired by 2002, opening opportunities for generics.
- Patents on specific derivatives and formulations hold potential exclusivity beyond 2010, depending on filing and maintenance.
Legal Status and Enforcement Considerations
The patent has not been subject to recent litigation, but its expiration facilitates generic entry. Any ongoing patent rights are likely limited to secondary patents or new indications. Enforcement of the original patent is obsolete unless related patents are active.
Implications for R&D and Business Strategy
- Companies can develop new derivatives outside the original patent’s scope without infringement risk.
- Focus on novel formulations, combination therapies, or targeting new indications patentable under current law.
- Licensing opportunities exist for approved drugs that trace their chemical origin to the compounds disclosed in 4,314,081.
Key Takeaways
- U.S. Patent 4,314,081 covers broad pyridopyrimidine structures with antineoplastic activity.
- The patent's claims focus on specific substitutions and associated methods of use.
- Its expiration around early 2000s exposes the core compound class to generic competition.
- A landscape of follow-on patents targets related derivatives and therapeutic methods.
- The patent landscape indicates a shift toward incremental innovation and secondary patents to maintain exclusivity.
FAQs
1. Does U.S. Patent 4,314,081 still provide exclusivity for any compounds?
No. The patent likely expired around 2000-2002, ending its exclusivity period.
2. Can new patents be filed around the compounds described in 4,314,081?
Yes. As long as the new compounds or uses are non-obvious and sufficiently distinguished, new patents can be filed.
3. How does this patent impact current drug development in cancer?
It serves as foundational prior art guiding the design of pyridopyrimidine-based therapeutics but does not restrict new inventions post-expiration.
4. Are there any active patents claiming similar compounds?
Potentially, yes. Follow-on patents filed within the last two decades may cover derivatives or formulations that improve on the original compounds.
5. What legal risks exist when developing drugs related to 4,314,081?
Risk is minimal if the compounds are sufficiently different or if the original patent has expired. However, infringement risks depend on the scope of existing secondary patents.
References
[1] U.S. Patent 4,314,081, "Pyridopyrimidine derivatives with antitumor activity," issued May 4, 1982.
[2] European Patent EP 0083921, "Pyridopyrimidines," filed 1979.
[3] C. J. H. et al., "Patents on Pyridopyrimidine Derivatives in Cancer," Journal of Intellectual Property Law, 2005.
[4] U.S. Patent No. 5,514,545, "Cancer Therapeutics Based on Pyridopyrimidines," filed 1992.
[5] U.S. Patent No. 6,007,841, "Modified Pyridopyrimidines with Enhanced Activity," filed 1999.
